Real world data in luminal like de novo metastatic breast cancer following guidelines recommendations.

e13029Background: De novo metastatic breast cancer (dnMBC) represents approximately 6–10% of breast cancer. In luminal-like dnMBC recommendation for endocrine therapy (ET) as first-line treatment is reported by the main international guidelines. Unfortunately studies show that around 30% of these patients receive chemotherapy (CT) as first treatment, despite the higher toxicity and no proved superior efficacy. Aim of this study was to describe the use of CT and ET as first-line treatment in real world scenario. Methods: This retrospective study analyzed our serie of consecutive patients (p) with luminal like dnMBC treated at the Basurto University Hospital (Spain) between 2006 and 2015. We analyzed overall survival (OS), progression free survival (PFS), first-line treatment choice (ET vs CT), and which factors were related with this choice. Results: Of 129 p. dnMBC, 84 p. luminal-like were identified. Median age 66.2 years (SD 14.43). Ductal carcinoma 69p. (82%), luminal B like 50p. (59.5%), only bone and...